Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 20NIH 12INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Breast Neoplasms 2Solid Tumor 1Sarcoma, Endometrial Stromal 1Pancreatitis, Chronic 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Genetic Diseases, Inborn 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma 1Brain Neoplasms 1Adrenocortical Adenoma 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT02781272 2023-06-05

EMBER

Angle plc

Completed
200 enrolled
Gynecologic

Ovarian Neoplasms

NCT02785731 2018-11-09

Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.

Angle plc

Completed
204 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡